Given this risk, we thought we'd take a look at whether Kalaris Therapeutics (NASDAQ:KLRS) shareholders should be worried about its cash burn. In this report, we will consider the company's annual ...

Q2 2025 Earnings Call Transcript June 17, 2025 Operator: Welcome to Lennar’s Second Quarter Earnings Conference Call.

The acquisition was announced on May 27 th with a price of $25 per share, which represents a 34.6% premium over the 30-day ...

With technology that’s so effective it’s invisible, the MMA organization is revolutionizing sports entertainment ...